Skip to main content
Clinical Trials/NCT04989751
NCT04989751
Enrolling By Invitation
Not Applicable

A Multicenter Phenotype-Genotype Analysis of Limb Girdle Muscular Dystrophy Patients in China

Huashan Hospital1 site in 1 country450 target enrollmentJuly 7, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
LGMD
Sponsor
Huashan Hospital
Enrollment
450
Locations
1
Primary Endpoint
Changes in NSAA score
Status
Enrolling By Invitation
Last Updated
2 years ago

Overview

Brief Summary

Limb-girdle muscular dystrophies (LGMD) are a series of rare progressive genetic disorders that are characterized by wasting and weakness of the voluntary proximal muscles. The onset of the disease is usually at young age, and most patients will be wheelchair-bound due to the progressive deterioration. Since currently genetic therapies for this disease are still immature, better natural history and genotype-phenotype studies are needed for preparing future therapies.

Detailed Description

This is multicentered-based, prospective, and observational study, which mainly focuses on the diagnosis and progression of limb-girdle muscular dystrophies (LGMD) in China. the investigators collect patient data including basic information, strength evaluations, genetic data, electromyography results, pathology imaging from muscle biopsies, and MRIs. Previously collected patient data may also be enrolled in this study.

Registry
clinicaltrials.gov
Start Date
July 7, 2021
End Date
December 1, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Chongbo Zhao

Professor

Huashan Hospital

Eligibility Criteria

Inclusion Criteria

  • Identified with variants regarding LGMD related genes revealed by genetic sequencing
  • Progressive weakness involving shoulder girdle and/or pelvic girdle
  • Myopathic changes in electromyography or in pathological studies

Exclusion Criteria

  • Identified with variants in other genes (non-LGMD related) that may cause muscular dystrophies

Outcomes

Primary Outcomes

Changes in NSAA score

Time Frame: Baseline, Year 1, Year 3, Year 5

The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale with a score range of 0-34. It is used to measure the functional motor abilities of ambulant patients with muscular dystrophy. A lower NSAA score indicates more severe damage to the participant's motor capability.

Secondary Outcomes

  • Changes in muscle fat infiltration(Baseline, Year 3, Year 5)
  • Changes in 10 Metre Walk Test (10MWT)(Baseline, Year 3, Year 5)
  • Changes in 6 Minute Walk Test(Baseline, Year 3, Year 5)

Study Sites (1)

Loading locations...

Similar Trials